GLPwatch
Papers (10389)
Page 165 of 174, ranked by citation count.
- Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity.
- Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis.
- Association of tirzepatide with erectile dysfunction in people with type 2 diabetes.
- Association of Glucagon-like Peptide-1 Receptor Agonist Use with Stroke and Mortality Outcomes in Asymptomatic Intracranial Atherosclerotic Disease: Propensity Score-Matched Real-World Analysis.
- Cardiovascular effects of incretin-based drugs in patients with and without a history of heart failure: a protocol for a systematic review, meta-analysis and trial sequential analysis of randomised controlled trials.
- Real-world treatment satisfaction with dulaglutide, and its influencing factors, in a Chinese population with type 2 diabetes mellitus.
- GLP-1 Receptor/Dual Agonists for Weight Loss: A Systematic Review and Network Meta-Analysis of RCTs.
- [The Beneficial Effects of Switching from Dipeptidyl Peptidase-4 Inhibitors to Dulaglutide on Plasma Glucose and Hemoglobin A1c Levels: A Case Report of Four Patients with Type 2 Diabetes].
- Comparative effectiveness and safety of novel antidiabetic agents in the management of obstructive sleep apnea: a systematic review, meta-analysis, and network meta-analysis.
- In type 2 diabetes, glargine and liraglutide each improved glycemic outcomes at 5 y vs. glimepiride or sitagliptin.
- Liraglutide Is Probably the Best Second Drug to Prevent Cardiovascular Events in Patients With Type 2 Diabetes Mellitus Who Take Metformin.
- Bronchopulmonary dysplasia induced by hyperoxia attenuated by A GLP-1 analog, Liraglutide, by regulating the ACE-2/Ang(1-7)/Mas receptor pathway.
- In patients ≥ 50 years with type 2 diabetes and CV disease or risk factors, dulaglutide reduced CV outcomes.
- Switch from premixed insulin analogue to degludec-liraglutide combination: a CGM study.
- The Gastrointestinal Safety of Orforglipron, a GLP-1 Receptor Agonist, in Adults With or Without Type 2 Diabetes: A Network Meta-Analysis of Randomized Controlled Trials.
- Tirzepatide as Adjunct to Insulin in Adults With Type 1 Diabetes and Overweight or Obesity: A Systematic Review of Randomized and Real-World Evidence.
- Disparities in Adolescent and Young Adult Obesity Medication Dispensing: A Retrospective Linked EHR-Pharmacy Cohort, 2020-2025.
- Oral delivery of liraglutide using CPP/hyaluronic acid-modified mesoporous silica nanoparticles: A virus-inspired strategy for intestinal absorption.
- [Medication or lifestyle for obesity? New medication is a wake-up call for the general practitioner].
- Comparative Effectiveness of Liraglutide and Dulaglutide in Heart Failure with Preserved Ejection Fraction: A Propensity Score-Matched Real-World Study.
- <sup>68</sup>Ga-labeled exendin-4 to image cardiac repair after myocardial infarction: From lizard venom to laboratory and beyond.
- In early Parkinson disease, daily subcutaneous lixisenatide reduced motor disability progression at 12 mo.
- Clinical Presentation of a Child With a Novel ALMS1 Variant Associated With Alström Syndrome and Favorable Response to GLP-1 Receptor Agonist Therapy.
- The safety and efficacy of semaglutide in people with schizophrenia spectrum disorders: systematic review and meta-analysis of randomised controlled trials.
- [Liraglutide for weight loss in overweight and obese adults].
- Retrospective chart review on psychiatric manifestations of GLP-1 agonist usage.
- Development of a Follow-Up Protocol for Patients Treated with Injectable Semaglutide for Weight Loss: Design of a Research Study in Community Pharmacy.
- Real-World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery.
- Antiemetic effect of acupressure wristbands for GLP-1 medication associated nausea.
- Glucose-Dependent Insulinotropic Polypeptide Receptors Are Expressed in the Lateral Septum and Reduce Electrically-Evoked Dopamine Release as well as the Ability of Cocaine to Increase Extracellular Dopamine.
- Exploratory Analysis of Liraglutide Effects on Obstructive Sleep Apnea and Health-Related Quality of Life in Individuals With Obesity and COPD: A Secondary Analysis of a Randomised Controlled Trial.
- The impact of nutrition, exercise, and pharmacotherapy on menstrual health in adolescents with overweight and obesity.
- Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Outcomes in Patients With Atherosclerotic Cardiovascular Disease and Obesity Without Diabetes.
- Switching patterns of GLP-1 receptor agonists from 2018 to 2025 in the largest private healthcare network in Poland.
- Hemoglobin A1c levels in patients with type 2 diabetes mellitus receiving oral semaglutide with versus without proton pump inhibitors: An exploratory study.
- Summary for Patients: Semaglutide or Dulaglutide Versus Empagliflozin for Risk for Death and Cardiovascular Outcomes Among Patients With Type 2 Diabetes.
- Health-Related Quality of Life and Work-Related Outcomes in People with Obesity or Overweight Treated with Tirzepatide or Other Obesity Medications: United States Results from the Adelphi Real World Obesity Disease Specific Programme™.
- After the Prescription: The Clinical Support Gap in Telehealth-Based GLP-1 Care.
- Oral delivery of GLP-1 analogues by recombinant Lactococcus lactis restores pancreatic islet structure through intestinal mucosal absorption in diabetic mice.
- Letter by Ma et al Regarding Article, "Neuroprotective Effects of the Glucagon-Like Peptide-1 Analog Exenatide After Out-of-Hospital Cardiac Arrest: A Randomized Controlled Trial".
- Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE-JP Trial.
- Is There a Causal Link Between GLP-1 Receptor Agonists and Non-Arteritic Anterior Ischaemic Optic Neuropathy? A Critique of the Clinical Evidence.
- Predicting Long-Term Weight Loss Using Self-Reported, Digitally Collected, Real-World Data After Initiation of Semaglutide for Overweight or Obesity.
- Glycemic and Cost Outcomes among Hispanic/Latino People with Type 2 Diabetes in the USA Initiating Dulaglutide versus Basal Insulin: a Real-World Study.
- Correction to: Dose-response effects on HbA<sub>1c</sub> and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.
- Real-world effects of incretin-based Obesity medications on body composition.
- Use of liraglutide in type 1 diabetes: implications for management.
- Real-world use of semaglutide in patients with type 2 diabetes and end-stage renal disease: a multicenter retrospective cohort study.
- Cardiovascular efficacy of tirzepatide: what real-world evidence promises.
- ICER report demonstrates both the value and challenges in financing of weight loss medications.
- The impact of adjuvant anti-obesity medications on 10-year weight loss outcomes after sleeve gastrectomy.
- Two new doses of dulaglutide (Trulicity) for diabetes.
- Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.
- Multimodal imaging reveals distinct cardiac benefits of dulaglutide versus dapagliflozin in a mouse model of glucotoxic cardiomyopathy.
- Peptide Marriages: Modular Assembly of Multi-Agonist Therapeutics.
- Semaglutide Is a New Once-Daily Oral Medication to Treat Type 2 Diabetes.
- Cost-Effectiveness of Pharmacologic Therapies for Metabolic Dysfunction-Associated Steatohepatitis With Significant Fibrosis in the United States.
- Orforglipron, quand le GLP-1 devient simple et oral.
- Dulaglutide slows kidney disease in type 2 diabetes - Author's reply.
- Case study on adverse reactions of dulaglutide: literature review.